Vaccine effectiveness against COVID-19 hospitalization in adults in France: A test negative case control study

被引：6

作者：

Ngyen, Liem Binh Luong ^{[1
]}

Bauer, Rebecca ^{[2
]}

Lesieur, Zineb ^{[3
]}

Galtier, Florence ^{[4
]}

Duval, Xavier ^{[5
]}

Vanhems, Philippe ^{[6
]}

Laine, Fabrice ^{[7
]}

Tattevin, Pierre ^{[8
,9
]}

Durier, Christine ^{[2
]}

Launay, Odile ^{[1
,3
]}

机构：

[1] Hop Cochin, AP HP, INSERM, CIC 1417, Paris, France

[2] INSERM, US19, Villejuif, France

[3] F CRIN I REIVAC, INSERM, Paris, France

[4] CHU Montpellier, St Eloi Hosp, INSERM, CIC 1411, Montpellier, France

[5] Hop Bichat Claude Bernard, AP HP, INSERM, CIC 1425, Paris, France

[6] Hosp Civils Lyon, Serv Hyg Epidemiol Infectiovigilance & Prevent, Lyon, France

[7] CHU Rennes, Inserm CIC 1414, Rennes, France

[8] CHU Rennes, Hop Pontchaillou, Serv Malad Infect, Rennes, France

[9] CHU Rennes, Hop Pontchaillou, Serv Reanimat Med, Rennes, France

来源：

INFECTIOUS DISEASES NOW | 2022年 / 52卷 / 01期

关键词：

Alpha variant; COVID-19; France; Vaccine; Vaccine effectiveness;

D O I：

10.1016/j.idnow.2021.12.002

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Background: Measuring vaccine effectiveness (VE) using real-life data is critical to confirm the effectiveness of licensed vaccine, which could strengthen vaccination adherence. Methods: We measured VE against adult COVID-19 hospitalization in five hospitals in France using a test negative design. We compared the odds of vaccinated patients hospitalized with COVID-19 with the odds of vaccinated patients hospitalized for the same symptoms with a negative test. Results: A total of 853 patients (463 cases and 390 controls) were included, with a total of 170 patients vaccinated (104 with one dose, 65 with two doses, and one with three doses). There were four cases of breakthrough infections, all in immunocompromised patients. The VE was 84.0% (CI0.95 = [72.6; 90.6]) for one dose and 96.2% (CI0.95 = [86.8; 98.9]) for two doses. Conclusion: Our results confirm the high VE of COVID-19 vaccine in France to prevent hospitalizations due to the alpha variant.

引用

页码：40 / 43

页数：4

共 50 条

[21] Reduction in COVID-19 Vaccine Effectiveness against SARS-CoV-2 Variants in Seoul according to Age, Sex, and Symptoms: A Test-Negative Case-Control Study
Gim, Hyerin
Oh, Soyoung
Lee, Heeda
Lee, Seul
Seo, Haesook
Park, Yumi
Park, Jae-Hyun
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2022, 19 (24)
[22] Vaccinating against a Novel Pathogen: A Critical Review of COVID-19 Vaccine Effectiveness Evidence
Black, Bernard
Thaw, David B.
MICROORGANISMS, 2024, 12 (01)
[23] CoronaVac vaccine is effective in preventing symptomatic and severe COVID-19 in pregnant women in Brazil: a test-negative case-control study
Enny S. Paixao
Kerry L. M. Wong
Flavia Jôse Oliveira Alves
Vinicius de Araújo Oliveira
Thiago Cerqueira-Silva
Juracy Bertoldo Júnior
Tales Mota Machado
Elzo Pereira Pinto Junior
Viviane S. Boaventura
Gerson O. Penna
Guilherme Loureiro Werneck
Laura C. Rodrigues
Neil Pearce
Mauricio L. Barreto
Manoel Barral-Netto
BMC Medicine, 20
[24] COVID-19 Vaccine Immunogenicity, Effectiveness and Safety in Frail Older Adults
Chou, Hsiao-Hui
Tseng, Hsiang-Kuang
Hwang, Lee-Ching
INTERNATIONAL JOURNAL OF GERONTOLOGY, 2022, 16 (03) : 175 - 179
[25] CoronaVac vaccine is effective in preventing symptomatic and severe COVID-19 in pregnant women in Brazil: a test-negative case-control study
Paixao, Enny S.
Wong, Kerry L. M.
Oliveira Alves, Flavia Jose
Oliveira, Vinicius de Araujo
Cerqueira-Silva, Thiago
Bertoldo Junior, Juracy
Machado, Tales Mota
Pinto Junior, Elzo Pereira
Boaventura, Viviane S.
Penna, Gerson O.
Werneck, Guilherme Loureiro
Rodrigues, Laura C.
Pearce, Neil
Barreto, Mauricio L.
Barral-Netto, Manoel
BMC MEDICINE, 2022, 20 (01)
[26] Duration of COVID-19 mRNA Vaccine Effectiveness against Severe Disease
Bansal, Devendra
Abdulmajeed, Jazeel
Al-Shamali, Maha H. M. A.
Albayat, Soha S. A.
Himatt, Sayed M.
Cyprian, Farhan S.
Chivese, Tawanda
Mundodan, Jesha M. A.
Khogali, Hayat S.
Baaboura, Rekayahouda
Kaleeckal, Anvar H.
Kandy, Mujeeb C.
Latif, Ali Nizar
Al-Kuwari, Mohamed Ghaith
Al-Romaihi, Hamad Eid
Al Khal, Abdullatif
Bertollini, Roberto
Al-Thani, Mohamed Hamad
Farag, Elmobashar
Doi, Suhail A. R.
VACCINES, 2022, 10 (07)
[27] COVID-19 vaccine effectiveness and variants in Nepal: study protocol for a test-negative case-control study with SARS-CoV-2 genetic sequencing
Bijukchhe, Sanjeev M.
O'Reilly, Peter J.
Theiss-Nyland, Katherine
Gurung, Meeru
Pokhrel, Bhishma
Kelly, Sarah
Acharya, Samita
Maharjan, Shreekrishna
Shrestha, Ashis
Pandey, Bimal
Lama, Mipsang
Shrestha, Ira
Voysey, Merryn
Eordogh, Agnes
Shrestha, Sonu
Feng, Elaine Shuo
Li, Grace
Shah, Ganesh
Pollard, Andrew J.
Shrestha, Shrijana
BMJ OPEN, 2023, 13 (04):
[28] Evaluation of the Real-World Effectiveness of Vaccines against COVID-19 at a Local Level: Protocol for a Test-Negative Case-Control Study
Brazete, Catia
Pinto, Marta
Sa, Ligia
Aguiar, Ana
Alves, Filipe
Duarte, Raquel
VACCINES, 2022, 10 (05)
[29] Effectiveness of the BNT162b2 XBB.1.5-adapted vaccine against COVID-19 hospitalization related to the JN.1 variant in Europe: a test-negative case-control study using the id.DRIVE platform
Nguyen, Jennifer L.
Mitratza, Marianna
Volkman, Hannah R.
de Munter, Leonie
Tran, Thao Mai Phuong
Marques, Catia
Mustapha, Mustapha
Valluri, Srinivas
Yang, Jingyan
Anton, Andres
Casas, Irma
Conde-Sousa, Eduardo
Drikite, Laura
Gruener, Beate
Icardi, Giancarlo
Kate, Gerrit Luit ten
Martin, Charlotte
Mira-Iglesias, Ainara
Orrico-Sanchez, Alejandro
Otero-Romero, Susana
Rohde, Gernot
Jodar, Luis
Mclaughlin, John M.
Bollaerts, Kaatje
ECLINICALMEDICINE, 2025, 79
[30] Effectiveness of the ChAdOx1 nCoV-19 Vaccine against Laboratory-confirmed Cases of COVID-19: A Test-negative Case-control Study from Central Kerala, India
Madhavikutty, Geethadevi
Raveendran, Ajith
Thomas, Ronnie
Murali, Asha joan
Mathew, Anju Chempakasserl
Lucas, Anupa
Akshayakumar, Sobha
JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2023, 17 (10) : LC28 - LC32

← 1 2 3 4 5 →